Kyverna Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kyverna Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-80.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 79% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +339%In 3 years sales changed by -100% while total assets changed by +339%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-38.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 67% of Healthcare companies in United States.
Cash Cushion Ratio
+71%Cash, after subtracting all debt, equals 71% of its market value (net cash).
Higher than 83% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Kyverna Therapeutics, Inc. made a loss over the last year. Kyverna Therapeutics, Inc. owes $0.25 for every $1 it owns. Kyverna Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKyverna Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.14The share price is 2.14 times Kyverna Therapeutics, Inc.'s book value per share, lower than 56% of Healthcare companies in United States.
Market cap
$354 MThe total market value of all of Kyverna Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 50% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$166 MWhat Kyverna Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.68Net worth divided by the number of shares. The share price of $5.73 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-87.2%Kyverna Therapeutics, Inc. lost 87.2% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
Owes vs Owns
0.25×Kyverna Therapeutics, Inc. owes $0.25 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Dividend yield
NoneKyverna Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossKyverna Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredKyverna Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashKyverna Therapeutics, Inc. held $250 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Kyverna Therapeutics, Inc.: $354 M ÷ $166 M (30 Jun 2026) = 2.1.
What is Kyverna Therapeutics, Inc.'s return on equity?
Kyverna Therapeutics, Inc. lost 87.2% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
How much does Kyverna Therapeutics, Inc. owe compared with what it owns?
Kyverna Therapeutics, Inc. owes $0.25 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Does Kyverna Therapeutics, Inc. pay a dividend?
No. Kyverna Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.